Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04797143

Impact of a Multidisciplinary Consultation Program on Drug Adherence in First Oral Anticancer Treatment

Status
Recruiting
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
Centre Hospitalier Universitaire, Amiens · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Oncology management has changed dramatically over the last decade with the approval and rapid adoption of newly targeted oral oncology medications. The movement to oral oncology medications has altered the balance of risks and adverse effects (AEs) in the treatment of cancer care. These treatments are associated with a different constellation of AEs and drug interactions. Patients receiving treatment with oral anticancer treatment (OAT) encounter several barriers to adherence, which may include limited access to specialty medications, severe adverse effects, complex medication regimens, and special handling precautions. Medication nonadherence not only reduces the efficacy of drug therapy but also has the potential to increase healthcare expenditures due to disease-related hospitalizations. The purpose of this study is to evaluate the drug adherence in cancer patients, using the medication possession ratio (MPR), before and after the implementation of a multidisciplinary consultation program (MCP), on initiation of OAT.

Conditions

Interventions

TypeNameDescription
DEVICEmultidisciplinary consultation programThe multidisciplinary consultation program (MCP) was divided into 3 steps: the first step involved a consultation with an oncologist, the second step involved a consultation with an oncology pharmacist, and the third step involved a meeting with a coordinating nurse (CN). The CN put in place a regular telephone follow-up with the patient, a few days later (7 to 15 days), to ensure adherence and tolerance of the oral anticancer treatment (OAT).

Timeline

Start date
2021-03-11
Primary completion
2026-03-01
Completion
2026-03-01
First posted
2021-03-15
Last updated
2025-04-02

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04797143. Inclusion in this directory is not an endorsement.